Events

Combating Obesity: Advancements in Treatment Options and Access to Care

CHI-PNG-for-Website

Please join California Healthcare Institute (CHI)* for an informational Congressional Briefing

Combating Obesity: Advancements in Treatment Options and Access to Care

Tuesday, May 6 at 9:00 a.m. EDT

B-318 Rayburn House Office Building
45 Independence Ave. SW
Washington, D.C. 20515

In 2014, an estimated 36 percent of adults in the United States are obese. People who are significantly overweight can face disastrous and debilitating health consequences, such as: heart disease, stroke, cancer, diabetes, dyslipidemia (too much fat in the blood), joint issues, osteoarthritis, sleep apnea and many others. According to a 2012 study published by the Journal of Health Economics, the economic costs of obesity are tremendous: Americans spend more than $190 billion each year on obesity-related medical expenses.

Obesity has become a significant public health policy challenge. However, the U.S. is making significant progress in the fight against obesity: the American Medical Association (AMA) declared in 2013 that obesity is a disease; and several biopharmaceutical companies have developed, or are developing, medications that – combined with diet, exercise and other lifestyle changes – can help obese patients lose and manage their weight, reducing their risks for heart disease, diabetes, osteoarthritis and other complications.

Please join us to learn more about the underlying science of obesity, the economic impact of obesity, the important role of anti-obesity therapies in disease management, and the critical need for patient access to care.

With introductory remarks from:

Scott Peters headshot

Rep. Scott Peters (CA-52)

This briefing will feature presentations from healthcare economics experts, clinicians, patient advocates, and biomedical innovators, including:

RSVP to Jenny Carey at (202) 974-6323 or carey@chi.org

This event is held in strict accordance with House and Senate Ethics rules.  Food and refreshments of a nominal value will be provided as allowed by House Rule 25, clause 5(a)(3)(U) and Senate Rule 35.1(d)(1)

*This event is supported through educational grants from Arena Pharmaceuticals, Eisai Inc., Orexigen Therapeutics, Takeda Pharmaceutical Company, and Vivus Inc.